


Amendments to the Claims:

The following listing of claims will replace all prior versions, and listings, of claims in the application:


1. (Original) A compound of formula (I)



or a pharmaceutically acceptable salt or ester thereof, wherein

X is

- 1) H,
- 2) aryl,
- 3) heteroaryl or
- 4) a group of formula



wherein aryl and heteroaryl can be unsubstituted or substituted with 1 to 4 substituents selected from **R^a**, as defined hereinafter;

Y is

- 1) H,
- 2) (C₁-C₆)alkyl,
- 3) (C₃-C₇)cycloalkyl or
- 4) (C₃-C₇)cycloalkyl-(C₁-C₃)alkyl;

Q is

- 1) aryl,
- 2) aryl-(C₁-C₆)alkyl,
- 3) heteroaryl or
- 4) heteroaryl-(C₁-C₆)alkyl;

wherein aryl and heteroaryl can be optionally substituted with 1 to 3 substituents selected from **R^a**; and alkyl can be optionally substituted with Cy;
Cy is cycloalkyl, heterocyclyl, aryl or heteroaryl;

A is

- 1) (C₁-C₆)alkyl,

- 2) (C₂-C₆)alkenyl,
- 3) (C₂-C₆)alkynyl,
- 4) Cy or
- 5) Cy-(C₁-C₆)alkyl;

wherein alkyl and cycloalkyl can be optionally substituted with 1 to 2 substituents selected from **R^c**, as defined hereinafter; and Cy can be optionally substituted with 1 to 3 substituents selected from **R^a**;

B is

- 1) N or
- 2) C(D);

D is independently

- 1) H,
- 2) halogen,
- 3) (C₁-C₆)alkyl,
- 4) (C₂-C₆)alkenyl,
- 5) (C₂-C₆)alkynyl,
- 6) -NR^bR^b,
- 7) -NO₂ or
- 8) -CN;

wherein R^b is to be defined hereinafter;

E is

- 1) CH₂,
- 2) CHR^b or
- 3) CR^bR^c;

R1 is

- 1) H,
- 2) (C₁-C₆)alkyl,
- 3) (C₂-C₆)alkenyl,
- 4) (C₂-C₆)alkynyl,
- 5) Cy,
- 6) Cy-(C₁-C₃)alkyl,
- 7) -(CH₂)_kC(O)NR^bR^b or
- 8) (C₁-C₆)alkoxy(C₁-C₆)alkyl;

wherein Cy can be unsubstituted or substituted with a group selected from **R^a** and alkyl, alkenyl, alkynyl and alkoxy can be unsubstituted or substituted with a group selected from **R^c**;

R2 is

- 1) H,
- 2) (C₁-C₉)alkyl,
- 3) (C₂-C₉)alkenyl,
- 4) (C₂-C₉)alkynyl,

- 5) Cy or
- 6) Cy-(C₁-C₃)alkyl;

wherein Cy can be unsubstituted or substituted with a group selected from **R^a** and alkyl, alkenyl and alkynyl can be unsubstituted or substituted with a group selected from **R^c**;

R³ is

- 1) H or
- 2) (C₁-C₆)alkyl;

R^a is independently

- 1) H,
- 2) halogen,
- 3) (C₁-C₆)alkyl,
- 4) (C₂-C₆)alkenyl,
- 5) (C₂-C₆)alkynyl,
- 6) Cy,
- 7) -OR^b,
- 8) -SR^b,
- 9) -NR^bR^b,
- 10) -NR^bC(N)NR^bR^b,
- 11) -C(O)R^b,
- 12) -C(O)NR^bR^b,
- 13) -NC(O)R^b,
- 14) -SO₂NR^bR^b,
- 15) -NO₂,
- 16) -CN,
- 17) -CF₃ or
- 18) amino-(C₁-C₆)alkyl;

R^b is independently

- 1) H,
- 2) (C₁-C₆)alkyl,
- 3) (C₂-C₆)alkenyl,
- 4) (C₂-C₆)alkynyl,
- 5) (C₃-C₇)cycloalkyl,
- 6) aryl,
- 7) heteroaryl,

or in the context of D, R¹, R^a and R^c, **R^b** and **R^b** together with the atom to which they are attached can also form a 5 to 6 membered ring containing 1 to 2 heteroatoms selected from N, O and S;

R^c is independently

- 1) H,
- 2) halogen,
- 3) Cy,

- 4) $-\text{CN}$,
- 5) $-\text{OR}^b$,
- 6) $-\text{SR}^b$,
- 7) $-\text{NR}^b\text{R}^b$ or
- 8) $-\text{NR}^b\text{C}(\text{N})\text{NR}^b\text{R}^b$;


k is an integer 0 or 1;

h is an integer from 0 to 4;

n is an integer 0 or 1;

m is an integer from 0 to 3;

with the proviso that the compound of formula I is not the compound



and provided that A in formula (I) is not 2-hydroxyethyl.


2. (Original) A compound according to claim 1, wherein

R² is

- 1) H,
- 2) (C₁-C₆)alkyl,
- 3) (C₂-C₆)alkenyl,
- 4) (C₂-C₆)alkynyl,
- 5) Cy or
- 6) Cy-(C₁-C₃)alkyl;

wherein Cy can be unsubstituted or substituted with a group selected from **R^a** and alkyl, alkenyl and alkynyl can be unsubstituted or substituted with a group selected from **R^c**.

3. (Currently Amended) A compound according to claim 1-~~or~~ 2, wherein the compound is a compound of formula IA




IA

or a pharmaceutically acceptable salt or ester thereof,

wherein A, Q, X, Y and n are as defined in claim 1 ~~or claim 2~~.

4. (Currently Amended) A compound according to claim 1 ~~or 2~~, wherein the compound is a compound of formula IB




IB

or a pharmaceutically acceptable salt or ester thereof,

wherein A, D, E, X, Y, h, m and n are as defined in claim 1 ~~or claim 2~~;

Q is aryl-(C₁)alkyl or heteroaryl-(C₁)alkyl, where aryl or heteroaryl are optionally substituted with 1 to 2 substituents selected from R^a.

5. (Currently Amended) A compound according to claim 1 ~~or 2~~, wherein the compound is a compound of formula IC




IC

or a pharmaceutically acceptable salt or ester thereof,

wherein R₂, A, D, E, Q, h, m and n are as defined in claim 1.

6. (Currently Amended) A compound according to claim 1 ~~or 2~~, wherein the compound is a compound of formula ID



ID

or a pharmaceutically acceptable salt or ester thereof,

wherein A, X, D and h are as defined in claim 1 ~~or claim 2~~;

Q is aryl-(C₁)alkyl or heteroaryl-(C₁)alkyl, where aryl or heteroaryl are optionally substituted with 1 to 2 substituents selected from R^a; and

m is an integer 1 or 2.

7. (Currently Amended) A compound according to claim 1 ~~or 2~~, wherein the compound of formula I is any of the compounds no 1 to 15 or 23 to 62 as described in the Examples.

8. (Currently Amended) A compound according to claim 1 ~~or 2~~, wherein the compound of formula I is (2*R*, 2'*R*)-5-Amino-2-{3'-naphthalen-1-yl-2'-[3-phenethyl-3-(2-pyridin-2-ylethyl)ureido]propionylamino}pentanamide, (2*R*)-*N*-(4-Aminobutyl)-3-(1*H*-indol-3-yl)-2-[3-(3-phenylpropyl)-3-(2-pyridin-2-ylethyl)ureido]propionamide, (2*S*, 2'*R*)-2-{2-[3,3-Bis(2-pyridin-2-ylethyl)ureido]-3-naphthalen-1-ylpropionylamino}-4-methylsulfanylbutyramide, (2*S*, 2'*R*)-4-Methylsulfanyl-2-{3'-naphthalen-1-yl-2'-[3-phenethyl-3-(2-pyridin-2-ylethyl)ureido]propionylamino}butyramide, (2*S*, 2'*R*)-3-Methyl-2-{3'-naphthalen-1-yl-2'-[3-phenethyl-3-(2-pyridin-2-ylethyl)ureido]propionylamino}butyramide, (2*R*)-*N*-cyclohexyl-3-naphthalen-1-yl-2-[3-phenethyl-3-(2-pyridin-2-ylethyl)ureido]propionamide, (2*S*, 2'*R*)-2-{3'-naphthalen-1-yl-2'-[3-phenethyl-3-(2-pyridin-2-ylethyl)ureido]propionylamino}-3-phenylpropionamide or (2*S*, 2'*R*)-2-{2-[3,3-bis(2-pyridin-2-ylethyl)ureido]-3'-naphthalen-1-ylpropionylamino}-3-methylbutyramide.

9. (Currently Amended) A compound according to ~~any of the claims 1 to 8~~ claim 1 where the compound is an SSTR1 selective agonist.

10. (Currently Amended) A compound according to ~~any of the claims 1 to 8~~ claim 1 where the compound is an SSTR1 selective antagonist.

11. (Currently Amended) A pharmaceutical composition comprising as active ingredient at least one compound according to ~~any of the claims 1 to 10~~ claim 1 and at least one pharmaceutically acceptable carrier.

12. (Currently Amended) ~~Use of a compound according to any of the claims 1 to 10 for the manufacture of a pharmaceutical preparation~~ A method for the treatment and/or prevention of a disease or condition responding to targeting with a selective SSTR1 compound, comprising administering to a patient with such a disease or condition a compound according to claim 1.

13. (Currently Amended) ~~The use~~ method according to claim 12, wherein the said disease or condition is a central nervous system disease or disorder, a disease or condition benefiting from the use of anti-proliferative agents, pathological condition in the retina and/or iris-ciliary body, diabetic complication, cancer or excessive proliferation of normal or malignant tissue.

14. (Currently Amended) ~~The use~~ method according to claim 12, wherein the said disease or condition is anxiety, depression or schizophrenia.

15. (Currently Amended) ~~The use~~ method according to claim 12, wherein the said disease or condition is prostatic cancer, benign prostatic hyperplasia, pancreatic cancer, thyroid cancer, brain tumor or gastro-intestinal tumor.

16. (Currently Amended) ~~The use~~ method according to claim 12, wherein the said disease or condition is diabetic retinopathy, diabetic nephropathy or diabetic neuropathy.

17. (Currently Amended) ~~The use~~ method according to claim 12, wherein the said disease or condition is angiogenesis, vascular restenosis, smooth muscle proliferation, endothelial cell proliferation, new blood vessel sprouting or neovascularization.

18. (Currently Amended) ~~Use of a compound of according to any of the claims 1 to 10 in combination with a detectable label,~~ A method for targeting tissues bearing SSTR1s for tissue imaging, comprising administering a compound according to claim 1 in combination with a detectable label.

19. (Currently Amended) ~~Use of a compound of according to any of the claims 1 to 10 as a carrier for another~~ A method for targeting a therapeutically active compound to be targeted to tissues bearing SSTR1s, comprising administering said therapeutically active compound with a compound according to claim 1 as a carrier for said therapeutically active compound.